Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
J Clin Neurosci ; 91: 306-312, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34373044

RESUMEN

BACKGROUND: Rapid Eye Movement sleep behavior disorder (RBD) is characterized by dream enactment and loss of muscle atonia during REM-sleep. RBD as a premotor feature occurred souvent in patients who develop Parkinson's disease. The glutamatergic, glycinergic, and GABA-ergic systems appear to play a crucial role in the pathogenesis of RBD. METHODS: The present exploratory longitudinal cross-over study aimed to observe the effect of safinamide on RBD symptoms. Thirty patients with PD and RBD were randomized into two groups (15 subjects each), those that received for a period of 3-months safinamide (50 mg/die) in addition (Group A + ) or in absence (Group B - ) to the usual antiparkinsonian therapy. Patients exploring the clinical and video-polysomnographic changes occurred during this pharmacological therapy. RESULTS: Twenty-two of 30 patients reported clear improvement in symptoms during safinamide treatment, and 16 were absolutely free from clinical RBD-symptoms at the end of the treatment. Eight patients reported slight improvement in RBD-symptoms. In 6/30 patients no substantial improvement was recorded about clinical RBD-symptoms had frightening dreams or from the bed after 1-week of treatment. In addition, after safinamide, the mean UPDRS-II and III scores decreased, while PDSS-2 score indicating an improvement in both motor symptoms and nocturnal sleep features. A significant reduction of sleep behavior disorder by questionnaire-Hong Kong-score (RBDQ-HS), mainly for two individual RBDQ-HK-items (dream related movements and failing out of bed) was registered. CONCLUSIONS: This pilot study indicated that safinamide is well tolerated and improves RBD-symptom in parkinsonian.


Asunto(s)
Enfermedad de Parkinson , Trastorno de la Conducta del Sueño REM , Alanina/análogos & derivados , Bencilaminas , Estudios Cruzados , Humanos , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Proyectos Piloto , Polisomnografía , Trastorno de la Conducta del Sueño REM/tratamiento farmacológico , Trastorno de la Conducta del Sueño REM/etiología
2.
Neurol Sci ; 42(12): 5277-5288, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33856582

RESUMEN

BACKGROUND: Although migraine is widespread and disabling, stigmatisation and poor awareness of the condition still represent barriers to effective care; furthermore, research on migraine individual and social impact must be enhanced to unveil neglected issues, such as caregiving burden. The project investigated the migraine illness experience through Narrative Medicine (NM) to understand daily life, needs and personal resources of migraneurs, their caregivers and clinicians, and to provide insights for clinical practice. METHODS: The project involved 13 Italian headache centres and targeted migraneurs, their caregivers and migraine specialists at these centres. Written narratives, composed by a sociodemographic survey and illness plot or parallel chart, were collected through the project's webpage. Illness plots and parallel charts employed open words to encourage participants' expression. Narratives were analysed through Nvivo software, interpretive coding and NM classifications. RESULTS: One hundred and seven narratives were collected from patients and 26 from caregivers, as well as 45 parallel charts from clinicians. The analysis revealed migraine perception in social, domestic and work life within the care pathway evolution and a bond between chaos narratives and day loss due to migraine; furthermore, narratives suggested the extent of the caregiving burden and a risk of underestimation of migraine burden in patients' and caregivers' life. CONCLUSION: The project represents the first investigation on migraine illness experience through NM simultaneously considering migraneurs', caregivers' and clinicians' perspectives. Comparing narratives and parallel charts allowed to obtain suggestions for clinical practice, while NM emerged as able to foster the pursuing of migraine knowledge and awareness.


Asunto(s)
Trastornos Migrañosos , Medicina Narrativa , Cuidadores , Humanos , Trastornos Migrañosos/terapia , Calidad de Vida , Dispositivos Aéreos No Tripulados
3.
J Clin Med ; 8(6)2019 Jun 22.
Artículo en Inglés | MEDLINE | ID: mdl-31234518

RESUMEN

OBJECTIVES: The aim of this study was to evaluate the performance of different analytic methods, such as liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), high-performance liquid chromatography-ultraviolet (HPLC-UV), enzyme-linked immunosorbent assay (EIA), and chemiluminescence immunoassays (CLIA), in order to highlight whether or not there is relative superiority amongst the assays. We analyzed two groups of subjects suffering from headache and two groups of healthy subjects. DESIGN AND METHODS: We performed a prospective, single-blind single-center control-group study on 220 subjects with migraine. Subjects of both sexes >10 years old and with 12 months' history of migraine were eligible for the study. As a control group, 120 healthy subjects were chosen by their family physician. RESULTS: LC-MS/MS evaluation documented that in all enrolled subjects (migraine and control groups), the serum vitamin D3 levels were lower with respect to the normal range (30-100 ng/mL), with a mean value of 15.4 ng/mL, without difference between sex. The mean values measured using HPLC-UV, EIA, and CLIA tests such as Liaison® and Architect® did not show significant differences compared to the values obtained using LC-MS/MS. CONCLUSIONS: In conclusion, the population generally has low values of the vitamin D3 hormone, and the suggested range should probably be revised. HPLC-UV and CLIA were found to have appropriate analytical values compared to the reference method (LC-MS/MS), so it is possible to suggest their routine use to optimize care.

4.
Curr Vasc Pharmacol ; 14(1): 98-105, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26411421

RESUMEN

Stroke is an acute condition characterized by a sudden decrease in blood flow to brain tissue, resulting in immediate deprivation of both glucose and oxygen. Different mechanisms are involved in the pathogenesis of stroke, but increasing evidence suggests that one of the processes worsening clinical outcome is inflammation with the synthesis and the release of pro-inflammatory cytokines that activate several cells contributing to the progression of brain injury. Monoclonal antibody therapy has proved useful and safe for the treatment of several systemic diseases. In contrast, the evidence is limited for the treatment of stroke. More studies are needed in order to standardize the method of treatment and establish if it is safe and effective.


Asunto(s)
Antiinflamatorios/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Accidente Cerebrovascular/tratamiento farmacológico , Animales , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/uso terapéutico , Isquemia Encefálica/patología , Citocinas/metabolismo , Glucosa/metabolismo , Humanos , Inflamación/tratamiento farmacológico , Inflamación/patología , Oxígeno/metabolismo , Accidente Cerebrovascular/patología
13.
J Headache Pain ; 6(4): 277-80, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16362686

RESUMEN

Headache occurs in a large proportion of young students. In this study we evaluated the incidence of headache in young people, examined associated factors and described the drug therapy used. A structured questionnaire was directly administered to 2700 students of secondary schools of Catanzaro. We recorded that headache symptoms started between 9 and 12 years of age. The incidence density was higher in people living in the city (84%) and in tobacco and alcohol users than non-users (p < 0.01). The most common drugs used were non-steroidal anti-inflammatory drugs. In 20% of people, this treatment induced the development of chronic headache. These data showed that morbidity from headache is often unrecognised and undertreated. Better management of headache symptoms and therapy could reduce the frequency of headache episodes, with a reduction of adverse drug reactions.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Cefalea/tratamiento farmacológico , Cefalea/epidemiología , Sulfonamidas/uso terapéutico , Aspirina/uso terapéutico , Niño , Femenino , Humanos , Incidencia , Masculino , Prevalencia , Encuestas y Cuestionarios
14.
J Headache Pain ; 6(4): 312-4, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16362697

RESUMEN

The impact of migraine headaches is one of the major public health problems in several industrialised countries, with many patients reporting frequent and significant disability. Previous studies have assessed general practitioners' (GPs) perceptions towards evidence-based medicine (EBM) and its influence on health care decisions. Of 500 questionnaires distributed, responses were received from 455 for a response rate of 91%. Respondents' awareness of technical terms used in EBM indicated that only 27.2% of GPs agreed that clinical trials are needed to evaluate the efficacy of treatments and this awareness was higher in those who learned about migraine from scientific journals or continuing education courses and who attended courses on epidemiology or EBM. Training and continuing educational programmes on EBM and guidelines in terms of treatments of headache for GPs are strongly needed.


Asunto(s)
Educación Médica Continua , Medicina Basada en la Evidencia , Trastornos Migrañosos/terapia , Médicos de Familia/educación , Adulto , Anciano , Femenino , Encuestas de Atención de la Salud , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/diagnóstico , Pautas de la Práctica en Medicina , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...